Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

The PCE was developed by the American College of Cardiology and American Heart Association and uses factors such as age, sex, ...

Please provide your email address to receive an email when new articles are posted on . In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

Obstructive sleep apnea (OSA) was associated with a notably higher risk of developing retinal vein occlusion across different demographic groups, with the greatest increase observed in people of ...